Please login to the form below

Not currently logged in
Email:
Password:

Dutch companies partner on vaccines

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio

Biotech company, Pepscan, is to partner with Immunovo to grow its vaccine portfolio. Pepscan focuses on protein mimicking technology for the generation of immune therapeutics.

Under the agreement, Immunovo will develop its therapeutic vaccine portfolio. Immunovo will pay an undisclosed cash sum to Pepscan and Pepscan will take a minority interest in Immunovo.

"Pepscan has recently refocused its R&D programme on the application of its proprietary CLIPSTM protein mimicry technology for the generation of monoclonal antibodies and therapeutic peptides," said Wim Mol, CEO of Pepscan.

"The agreement with Immunovo allows Pepscan to fully concentrate its resources on a focused execution of its research programme. We consider Immunovo an ideal partner to enhance the value of the therapeutic vaccine portfolio we have developed over the years."

Joost van Bree, CEO of Immunovo, said: "We are very pleased with the partnership with Pepscan on the therapeutic vaccine portfolio. Pepscan created a rich development pipeline of therapeutic vaccines, of which the most advanced product is in phase II clinical development.

"We are confident that with our specific expertise we will be able to expedite the development of this portfolio, which also includes a proprietary anti-VEGF-A vaccine that could be useful for the treatment of certain cancers."

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to present one or more peptides in a structurally constrained configuration.

28th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics